{"id":"ikzf3","name":"IKZF3 (Aiolos)","symbol":"IKZF3","route":"/targets/ikzf3/","asOf":"2026-09-22","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13178","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000161405","uniprot":"https://www.uniprot.org/uniprotkb/Q9UKT9/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q9UKT9","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL4739707","open-targets":"https://platform.opentargets.org/target/ENSG00000161405","civic":"https://civicdb.org/genes/22806/summary","oncokb":"https://www.oncokb.org/gene/IKZF3","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=IKZF3","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=IKZF3","depmap":"https://depmap.org/portal/gene/IKZF3?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000161405-IKZF3","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/22806","omim":"https://www.omim.org/entry/606221"}],"products":[{"id":"golcadomide","name":"Golcadomide","status":"phase-3","modality":"Molecular glue degrader (CELMoD, IKZF1/3)","route":"/drugs/golcadomide/"},{"id":"lenalidomide","name":"Lenalidomide","status":"approved","modality":"Immunomodulatory drug (cereblon E3 ligase modulator)","route":"/drugs/lenalidomide/"},{"id":"pomalidomide","name":"Pomalidomide","status":"approved","modality":"Oral cereblon E3 ligase modulator (IMiD)","route":"/drugs/pomalidomide/"}],"trials":[{"id":"nct04680052","name":"A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Pa","nct":"NCT04680052","phase":"3","status":"active"},{"id":"nct06956170","name":"All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo","nct":"NCT06956170","phase":"3","status":"active"},{"id":"nct04404283","name":"Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL","nct":"NCT04404283","phase":"3","status":"active"},{"id":"frontmind","name":"frontMIND","nct":"NCT04824092","phase":"3","status":"positive"},{"id":"cepheus","name":"CEPHEUS","nct":"NCT03652064","phase":"3","status":"positive"},{"id":"imroz","name":"IMROZ","nct":"NCT03319667","phase":"3","status":"positive"},{"id":"perseus","name":"PERSEUS","nct":"NCT03710603","phase":"3","status":"positive"},{"id":"nct03151811","name":"A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide","nct":"NCT03151811","phase":"3"},{"id":"determination","name":"DETERMINATION","nct":"NCT01208662","phase":"3","status":"positive"},{"id":"augment","name":"AUGMENT","nct":"NCT01938001","phase":"3","status":"positive"},{"id":"maia","name":"MAIA","nct":"NCT02252172","phase":"3","status":"positive"},{"id":"relevance","name":"RELEVANCE","nct":"NCT01476787","phase":"3","status":"mixed"},{"id":"ifm-2009","name":"IFM 2009","nct":"NCT01191060","phase":"3","status":"positive"},{"id":"remarc","name":"REMARC","nct":"NCT01122472","phase":"3","status":"mixed"},{"id":"nct06464991","name":"A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)","nct":"NCT06464991","phase":"3","status":"recruiting"},{"id":"nct05888493","name":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","nct":"NCT05888493","phase":"3","status":"active"},{"id":"nct06413498","name":"A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma","nct":"NCT06413498","phase":"3","status":"active"},{"id":"nct07391657","name":"A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela","nct":"NCT07391657","phase":"3","status":"recruiting"},{"id":"nct05455320","name":"A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination Wi","nct":"NCT05455320","phase":"3","status":"active"},{"id":"nct06208150","name":"A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez","nct":"NCT06208150","phase":"3","status":"active"},{"id":"nct05572515","name":"A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With","nct":"NCT05572515","phase":"3","status":"active"},{"id":"nct03539744","name":"A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) ","nct":"NCT03539744","phase":"3","status":"active"},{"id":"nct04712097","name":"A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomi","nct":"NCT04712097","phase":"3","status":"active"},{"id":"nct06679101","name":"A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethas","nct":"NCT06679101","phase":"3","status":"recruiting"},{"id":"nct05438043","name":"A Study of Daratumumab","nct":"NCT05438043","phase":"3","status":"active"},{"id":"nct06508658","name":"A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcita","nct":"NCT06508658","phase":"3","status":"active"},{"id":"nct05552222","name":"A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal","nct":"NCT05552222","phase":"3","status":"recruiting"},{"id":"nct07742215","name":"A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)","nct":"NCT07742215","phase":"3","status":"recruiting"},{"id":"nct05100862","name":"A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphom","nct":"NCT05100862","phase":"3","status":"active"},{"id":"nct04224493","name":"A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus ","nct":"NCT04224493","phase":"3","status":"active"},{"id":"nct05827016","name":"A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly","nct":"NCT05827016","phase":"3","status":"active"},{"id":"nct06911502","name":"A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Rela","nct":"NCT06911502","phase":"3","status":"recruiting"},{"id":"nct06045806","name":"A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alo","nct":"NCT06045806","phase":"3","status":"active"},{"id":"nct06084936","name":"A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma","nct":"NCT06084936","phase":"3","status":"recruiting"},{"id":"nct05519085","name":"A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Re","nct":"NCT05519085","phase":"3","status":"recruiting"},{"id":"nct05623020","name":"A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide","nct":"NCT05623020","phase":"3","status":"recruiting"},{"id":"nct05020236","name":"A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments","nct":"NCT05020236","phase":"3","status":"recruiting"},{"id":"nct06149286","name":"A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participant","nct":"NCT06149286","phase":"3","status":"recruiting"},{"id":"nct05730036","name":"A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Re","nct":"NCT05730036","phase":"3","status":"recruiting"},{"id":"cartitude-6","name":"CARTITUDE-6","nct":"NCT05257083","phase":"3","status":"active"},{"id":"drammatic","name":"DRAMMATIC","nct":"NCT04071457","phase":"3","status":"active"},{"id":"nct06082102","name":"Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma","nct":"NCT06082102","phase":"3","status":"recruiting"},{"id":"golseek-1","name":"GOLSEEK-1","nct":"NCT06356129","phase":"3","status":"active"},{"id":"nct04270409","name":"Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma","nct":"NCT04270409","phase":"3","status":"active"},{"id":"nct06152575","name":"MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other","nct":"NCT06152575","phase":"3","status":"recruiting"},{"id":"mosun-len-mzl","name":"Mosunetuzumab with lenalidomide in relapsed marginal zone lymphoma","nct":"NCT06006117","phase":"3","status":"active"},{"id":"nct06220032","name":"Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma","nct":"NCT06220032","phase":"3","status":"recruiting"},{"id":"nct06158841","name":"Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto","nct":"NCT06158841","phase":"3","status":"active"},{"id":"nct05371093","name":"Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma","nct":"NCT05371093","phase":"3","status":"active"},{"id":"nct07764978","name":"Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT","nct":"NCT07764978","phase":"3","status":"recruiting"},{"id":"nct06191744","name":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease ","nct":"NCT06191744","phase":"3","status":"active"},{"id":"nct05409066","name":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease ","nct":"NCT05409066","phase":"3","status":"active"},{"id":"nct05429268","name":"Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (","nct":"NCT05429268","phase":"3","status":"active"},{"id":"nct05317416","name":"Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant","nct":"NCT05317416","phase":"3","status":"active"},{"id":"nct07095452","name":"A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lena","nct":"NCT07095452","phase":"2/3","status":"recruiting"},{"id":"nct01772420","name":"Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia","nct":"NCT01772420","phase":"2","status":"completed"},{"id":"l-mind","name":"L-MIND","nct":"NCT02399085","phase":"2","status":"positive"},{"id":"nct06835530","name":"A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)","nct":"NCT06835530","phase":"2","status":"recruiting"},{"id":"nct06577025","name":"A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Ind","nct":"NCT06577025","phase":"2","status":"active"},{"id":"nct07312188","name":"A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma","nct":"NCT07312188","phase":"2","status":"recruiting"},{"id":"nct04133636","name":"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Mul","nct":"NCT04133636","phase":"2","status":"active"},{"id":"nct07189065","name":"A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma","nct":"NCT07189065","phase":"2","status":"recruiting"},{"id":"nct05283720","name":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neopl","nct":"NCT05283720","phase":"2","status":"active"},{"id":"nct07227311","name":"A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult","nct":"NCT07227311","phase":"2","status":"recruiting"},{"id":"nct06425302","name":"A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma","nct":"NCT06425302","phase":"2","status":"active"},{"id":"nct07018050","name":"Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma","nct":"NCT07018050","phase":"2","status":"recruiting"},{"id":"nct04782687","name":"Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma","nct":"NCT04782687","phase":"2","status":"active"},{"id":"nct07150104","name":"Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants Wi","nct":"NCT07150104","phase":"1/2","status":"active"},{"id":"nct07150091","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM","nct":"NCT07150091","phase":"1/2","status":"active"},{"id":"nct05222555","name":"Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients","nct":"NCT05222555","phase":"1/2","status":"active"},{"id":"nct02180711","name":"Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma","nct":"NCT02180711","phase":"1/2","status":"active"},{"id":"nct04669171","name":"A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma","nct":"NCT04669171","phase":"1/2","status":"recruiting"},{"id":"nct04973605","name":"A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Darat","nct":"NCT04973605","phase":"1/2","status":"recruiting"},{"id":"nct03930953","name":"A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory No","nct":"NCT03930953","phase":"1/2","status":"active"},{"id":"nct05583617","name":"A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma","nct":"NCT05583617","phase":"1/2","status":"recruiting"},{"id":"nct04246086","name":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokineti","nct":"NCT04246086","phase":"1/2","status":"active"},{"id":"nct06953960","name":"A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma ","nct":"NCT06953960","phase":"1/2","status":"recruiting"},{"id":"nct06090539","name":"A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas","nct":"NCT06090539","phase":"1/2","status":"recruiting"},{"id":"nct06892522","name":"A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe","nct":"NCT06892522","phase":"1/2","status":"recruiting"},{"id":"nct05950165","name":"A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Ly","nct":"NCT05950165","phase":"1/2","status":"active"},{"id":"nct05714839","name":"A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatme","nct":"NCT05714839","phase":"1/2","status":"recruiting"},{"id":"nct06106945","name":"AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma","nct":"NCT06106945","phase":"1/2","status":"recruiting"},{"id":"nct04110301","name":"MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)","nct":"NCT04110301","phase":"1/2","status":"recruiting"},{"id":"nct04126200","name":"Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple","nct":"NCT04126200","phase":"1/2","status":"active"},{"id":"nct04663347","name":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","nct":"NCT04663347","phase":"1/2","status":"active"},{"id":"nct06087653","name":"Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)","nct":"NCT06087653","phase":"1/2","status":"recruiting"},{"id":"nct02343042","name":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","nct":"NCT02343042","phase":"1/2","status":"recruiting"},{"id":"nct04068597","name":"Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies","nct":"NCT04068597","phase":"1/2","status":"recruiting"},{"id":"nct04661007","name":"To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL","nct":"NCT04661007","phase":"1/2","status":"active"}],"pathways":[],"companies":["bms","natco"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[{"class":"cd3-bispecific","mechanism":"T-cell exhaustion and depletion","category":"pharmacology"}],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}